Head-to-head · WeighScore
CoraDoc vs Zealthy
The verdict
CoraDoc takes it — 76.5/100 to 46.7/100.
CoraDoc grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. CoraDoc is a nationwide (all 50 states) doctor-prescribed GLP-1 weight-loss telehealth service offering compounded semaglutide (from $99/mo) and tirzepatide (from $165/mo) as flat, no-subscription programs.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | CoraDoc | Zealthy |
|---|---|---|
| WeighScore | 76.5/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #49 | #496 |
| Semaglutide | $99/mo (all doses, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $165/mo (all doses, compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #49 · C
Strengths
- Low flat pricing — compounded semaglutide from $99/mo, tirzepatide from $165/mo, no subscription
- Triple Free Promise: free provider visit, free 2-day shipping, and free supplies included
- Available in all 50 states; HSA/FSA plus Afterpay/Klarna/Affirm; full refund if not approved
- Full legal suite published (Terms, Privacy, Refund Policy); board-certified providers
Where it loses points
- Lowest $99 price is the longest-commitment tier (programs range about $99-$199/mo)
- Compounding pharmacy partner not named
- 'LegitScript Certified' is stated prominently but was not independently verified here
- Operating legal entity not clearly named on the site
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.